Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis
Andrea Casadei‐Gardini(Vita-Salute San Raffaele University), Alessandro Cucchetti(Ospedale G.B. Morgagni - L.Pierantoni), Margherita Rimini(Vita-Salute San Raffaele University), Kunihiko Tsuj(Teine Keijinkai Hospital), Hidenori Toyoda(Ogaki Municipal Hospital), Fabio Piscaglia(Azienda USL di Bologna), Mario Scartozzi(University of Cagliari), Caterina Vivaldi(Scuola Superiore Sant'Anna), Shigeo Shimose(Kurume University), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Stefano Cascinu(Vita-Salute San Raffaele University), Takashi Kumada(Gifu Kyoritsu University), Shinya Fukunishi(Osaka Medical and Pharmaceutical University), Ei Itobayashi(Asahi General Hospital), Sara Lonardi(Istituto Oncologico Veneto), Gianluca Masi(University of Pisa), Lorenza Rimassa(Humanitas University), Caterina Soldà(Istituto Oncologico Veneto), Toshifumi Tada(Himeji Red Cross Hospital), Hyung‐Don Kim(University of Ulsan), Masanori Atsukawa(Nippon Medical School), Nicola Silvestris(University of Messina), Changhoon Yoo(Ulsan College), L.G. Frassineti(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Hironori Koga(Kurume University), Yeonghak Bang(Himeji Red Cross Hospital), Takuji Torimura(Omuta hospital)
Cited by 60
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k